Save to Existing Project
Save to a New Project
NCEs for innovative therapeutic targets in inflammatory/immunologic diseases.
Zambon's R&D core competences range from hit-to-lead optimization up to full drug development. Its Lead Optimization Unit is capable to quickly bridge the gap between hit discovery and pre-clinical development and to reduce the risk of failures in clinical development. Zambon's R&D wants to become a valuable partner for all those Drug Discovery companies that want to add value to their lead molecules and see their candidate drugs enter riskless into development.
Type of Business Relationship Sought
<p>Companies having proprietary hits/lead compounds for innovative targets or proprietary targets and screening capabilities, will find a dynamic group capable to either optimize existing compounds or discover new hits. Zambon business model is based on collaboration aiming at bringing values to all partners. Roles and responsibilities can be flexibly arranged to obtain a successful and well-balanced relationship among partners.</p>
Last Updated Feb 2017